Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology

2017 ◽  
Vol 34 (5) ◽  
pp. 422-427
Author(s):  
Tomasz Wasniewski ◽  
Izabela Woclawek-Potocka
2015 ◽  
Vol 34 (5) ◽  
pp. 2760-2767 ◽  
Author(s):  
TOMASZ WASNIEWSKI ◽  
IZABELA WOCLAWEK-POTOCKA ◽  
DOROTA BORUSZEWSKA ◽  
ILONA KOWALCZYK-ZIEBA ◽  
EMILIA SINDEREWICZ ◽  
...  

Tumor Biology ◽  
2013 ◽  
Vol 34 (6) ◽  
pp. 4007-4016 ◽  
Author(s):  
Katarzyna Jarzabek ◽  
Mariusz Koda ◽  
Malgorzata Walentowicz-Sadlecka ◽  
Marek Grabiec ◽  
Piotr Laudanski ◽  
...  

2019 ◽  
Vol 853 ◽  
pp. 11-17
Author(s):  
Kazuyuki Sakamoto ◽  
Yukiko Noguchi ◽  
Koji Ueshima ◽  
Akiyoshi Ohtake ◽  
Shuichi Sato ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Emma S. Scott ◽  
Andrzej S. Januszewski ◽  
Luke M. Carroll ◽  
Gregory R. Fulcher ◽  
Mugdha V. Joglekar ◽  
...  

AbstractTo determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.


MedChemComm ◽  
2015 ◽  
Vol 6 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Inés González-Gil ◽  
Debora Zian ◽  
Henar Vázquez-Villa ◽  
Silvia Ortega-Gutiérrez ◽  
María L. López-Rodríguez

The current status of the LPA1receptor and its ligands in the drug development pipeline is reviewed.


2021 ◽  
Vol 22 (12) ◽  
pp. 6216
Author(s):  
Monika Englert-Golon ◽  
Mirosław Andrusiewicz ◽  
Aleksandra Żbikowska ◽  
Małgorzata Chmielewska ◽  
Stefan Sajdak ◽  
...  

Ovarian cancer remains the leading cause of death due to gynecologic malignancy. Estrogen-related pathways genes, such as estrogen receptors (ESR1 and ESR2) and their coregulators, proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), and proto-oncogene tyrosine-protein kinase c-Src (SRC) are involved in ovarian cancer induction and development, still they require in-depth study. In our study, tissue samples were obtained from 52 females of Caucasian descent (control group without cancerous evidence (n = 27), including noncancerous benign changes (n = 15), and the ovarian carcinoma (n = 25)). Using quantitative analyses, we investigated ESRs, PELP1, and SRC mRNA expression association with ovarian tumorigenesis. Proteins’ presence and their location were determined by Western blot and immunohistochemistry. Results showed that PELP1 and SRC expression levels were found to differ in tissues of different sample types. The expression patterns were complex and differed in the case of ovarian cancer patients compared to controls. The most robust protein immunoreactivity was observed for PELP1 and the weakest for ESR1. The expression patterns of analyzed genes represent a potentially interesting target in ovarian cancer biology, especially PELP1. This study suggests that specific estrogen-mediated functions in the ovary and ovary-derived cancer might result from different local interactions of estrogen with their receptors and coregulators.


Sign in / Sign up

Export Citation Format

Share Document